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810results in an incidence of cardiac
dysfunction on the order of 18%,
with 2% to 4% developing severe
symptomatic heart failure (HF)
(1–3). Retrospective analyses sug-
gest a greater risk of dysfunction in
the nonclinical trial population.
Data from the Cancer Research
Network showed that the use of
anthracyclines and trastuzumab in
combination was associated with
a >7-fold increased risk of HF or
cardiomyopathy (4).
As such, there remains a funda-
mental need to identify patients
with cancer undergoing treatment
with these agents who are at high
risk for cardiac complications.
Early identiﬁcation of subclinical
cardiac dysfunction could enable
the institution of cardioprotective
strategies, prevent the interruptionor discontinuation of necessary cancer therapy, and reduce early
and late cardiovascular and oncologicalmorbidity andmortality.
The methods currently used to identify patients at risk for
cardiotoxicity are inadequate. Screening of patients before
treatment and monitoring of cardiac function during therapy
have relied traditionally on left ventricular ejection fraction
(LVEF) (5). However, assessment of LVEF lacks the
sensitivity to detect early subclinical changes or predict
subsequent declines in function with treatment (6,7). Newer
metrics are needed to identify vulnerable patients during the
pre-clinical stage of cardiotoxicity; in other cardiovascular
diseases, the assessment of multiple biomarkers has been
shown to be of incremental utility in identifying patients at
increased risk for adverse outcomes (8–10).
The overall objective of this study was to determine the
potential utility of biomarkers for the early identiﬁcation of
patients with breast cancer at risk for cardiac dysfunction.
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revised manuscript received October 11, 2013,risk of subsequent cardiotoxicity in a multicenter cohort of
78 patients with breast cancer undergoing therapy with
doxorubicin and trastuzumab. We hypothesized that the
following cardiovascular biomarkers could be mechanistically
relevant to cardiotoxicity with cancer therapy: ultrasensitive
troponin I (TnI) (cardiomyocyte injury), high-sensitivity
C-reactive protein (CRP) (inﬂammation), N-terminal pro–
B-type natriuretic peptide (NT-proBNP) (neurohormonal
activation), growth differentiation factor (GDF)-15 (inﬂam-
mation and oxidative stress), myeloperoxidase (MPO) (ox-
idative stress), placental growth factor (PlGF) (angiogenesis),
soluble fms-like tyrosine kinase receptor (sFlt)-1 (vascular
remodeling), and galectin (gal)-3 (ﬁbrosis). Our objectives
were to determine whether individual biomarker levels, early
changes in biomarker levels, or a combination of biomarkers
could predict subsequent cardiotoxicity in patients treated with
doxorubicin and trastuzumab.Methods
Study population. The study population consisted of
outpatients with HER2-positive breast cancer recruited
across 4 centers as previously reported (11,12). Patients with
HER2-positive breast cancer who were scheduled to
undergo adjuvant therapy with an anthracycline-containing
regimen followed by taxanes and trastuzumab were in-
cluded. This regimen typically consisted of doxorubicin
(60 mg/m2) and cyclophosphamide (600 mg/m2) every
3 weeks for 4 cycles. At 3 months, paclitaxel (80 mg/m2) was
administered concurrently with trastuzumab every week for
12 weeks; trastuzumab was then continued every 3 weeks to
complete 1 year of therapy. Patients with an LVEF <50%
before chemotherapy or those who were unwilling or unable
to provide informed consent were excluded. This study
consisted of participants with biomarker data who completed
the protocol.
Participants were studied before chemotherapy and at
standardized intervals every 3 months during anthracycline,
paclitaxel, and trastuzumab therapy using serial question-
naires and echocardiograms for a total of 6 study visits per
participant (Fig. 1). Transthoracic echocardiograms were
acquired using Vivid 7 or E9 (GE Healthcare, Milwaukee,
Wisconsin) at these time intervals. Blood samples were
obtained at baseline, 3 months, and 6 months, processed,
and stored at 80C until the time of assay. The primary
endpoint of cardiotoxicity was the Cardiac Review and
Evaluation Committee deﬁnition of trastuzumab-associated
cardiotoxicity, that is, a reduction in LVEF of 5%
to <55% with symptoms of HF or an asymptomatic
reduction of LVEF of 10% to <55% (1).
All participants provided written informed consent, and
the protocol was approved by the institutional review boards
of the participating institutions.
Echocardiography. Digital echocardiograms were analyzed
on the EchoPAC workstation (GE Healthcare). Left ventric-
ular end-diastolic and -systolic volumes were obtained using
Baseline 3 months (post 
Anthracyclines) 
6 months 9 months 12 months 15 months 
Anthracyclines 
Trastuzumab/ 
Paclitaxel 
Trastuzumab 
Biomarkers  
(Visit 1) 
Biomarkers  
(Visit 2) 
Interval Change 
Echocardiogram and Questionnaire obtained at Baseline, 3, 6, 9, 12, and 15 months 
Biomarkers 
Figure 1 Study Protocol
Participants were studied before chemotherapy and at standardized intervals every 3 months during anthracycline, paclitaxel, and trastuzumab therapy using serial
questionnaires and echocardiograms for a total of 6 study visits per participant. Biomarkers were measured at baseline (visit 1), 3 months (visit 2), and 6 months.
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811Simpson’smethod of discs in the apical 4- and 2-chamber views
as recommended by theAmerican Society ofEchocardiography
(13). Ejection fraction was calculated from left ventricular
volumes as follows: (end-diastolic volume – end-systolic
volume)/end-diastolic volume  100%. All tracings were
made by a single observer at a centralized reading center who
was blinded to all other clinical or biomarker data.
Laboratory analyses. Biomarkers were measured from
banked plasma stored at 80C until assay. Ultrasensitive
TnI and NT-proBNP were measured on the Dimension
Vista 500 Intelligent Laboratory System (Siemens
Healthcare Diagnostics, Deerﬁeld, Illinois) using a 1-step,
homogeneous, sandwich chemiluminescent pre-commercial
immunoassay on the basis of Loci technology. High-
sensitivity CRP was measured using a standard Architect
immunoassay (Abbott Laboratories, Abbott Park, Illinois).
GDF-15, MPO, PlGF, sFlt-1, and gal-3 were all measured
using prototype Architect chemiluminescent 2-step
microparticle-based immunoassays (Abbott Laboratories).
Full details are provided in the Online Appendix.
Statistical methods. Data are described using summary
statistics, that is, medians with interquartile range and means
with SDs for continuous variables and proportions for
categorical variables. The Wilcoxon test was used to assess
the change in each biomarker concentration from baseline to
3 months (i.e., visit 2, the ﬁrst follow-up visit). The majority
of biomarkers were remeasured at the 3-month visit (in 90%
to 95% of patients) and in 5% to 10% of patients at the
6-month visit. This follow-up measurement is thus described
as the visit 2 measurement, with the understanding that it
primarily represents a change from baseline to 3 months.
Sensitivity analyses revealed that our results were very similar,
irrespective of whether we deﬁned visit 2 based strictly on
only the 3-month visit or included those patients who had
a 6-month value despite a missing 3-month value.Given that the objective of this study was to focus speciﬁ-
cally on early changes in markers, we determined the associ-
ation between the risk of cardiotoxicity and biomarker levels at
baseline and visit 2 and changes in levels from baseline to visit
2. To better compare biomarkers, the predictors were
normalized by the SD in either the biomarker level or the
change in level as appropriate. Candidate biomarkers with p
values <0.20 in univariable models were then individually
added to a model containing either the baseline value or
change in TnI to determine whether there was additional
information that could be obtained from markers in combi-
nation. Kaplan-Meier plots were used to illustrate the inci-
dence of cardiotoxicity according to interval changes in
biomarkers. To conceptualize the combined effect of the
marker changes, we used the ﬁnal model to predict car-
diotoxicity over time at the 10th, 50th, and 90th percentile of
the interval change in the 2 biomarkers in the ﬁnal model.
Analyses were performed using interval-censored time-to-
event methods and a parametric Weibull survival model
because cardiotoxicity was evaluated at visits separated by 3-
month intervals andwas thus both left and right censored (14).
For a 2-sided type I error rate of 0.05, a sample size of
78 patients, and an event rate of approximately 30%, this
study would have 80% power to detect relatively large hazard
ratios (HRs), on the order of 1.78, per SD in biomarker or
biomarker change (PASS 2008, Kaysville, Utah). Analyses
were performed using R 2.15 (R Development Core Team,
Vienna, Austria) and the R package Icens (Gentleman and
Vandal, Bioconductor, and R Project for Statistical
Computing).Results
Patient population. The baseline characteristics of the
study cohort are shown in Table 1. Over a maximal follow-up
Table 1 Patient Characteristics (N ¼ 78)
Age (yrs) 50.0 (42.0–56.8)
Body mass index (kg/m2) 25.1 (22.2–27.2)
Tobacco use 7 (9)
Breast cancer side
Left 38 (49)
Bilateral 6 (8)
Hypertension 21 (27)
Diabetes 1 (1)
Hyperlipidemia 18 (23)
Radiotherapy 46 (60)
Use of an ACE-inhibitor 13 (17)
Use of a beta-blocker 10 (13)
Baseline LVEF (IQR) 64 (61–68)
Values are median (interquartile range) or n (%).
ACE ¼ angiotensin-converting enzyme; LVEF ¼ left ventricular ejection fraction.
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812period of 15 months, there were a total of 23 outcomes (24%)
as deﬁned by the Cardiac Review and Evaluation Committee
criteria for cardiotoxicity. The median change in LVEF
among those patients who experienced cardiotoxicity was
15% (interquartile range: 12% to 17%). One of these patients
had a decline in ejection fraction of 5% to <55% with
symptoms. Of the remaining 22 patients, 18 had a decline
of 10% to <55% without symptoms and 4 patients had
a decline of 10% to <55% with symptoms. The maximal
changes in ejection fraction according to cardiotoxicity are
displayed graphically in Online Figure 1. Among the
participants who experienced cardiotoxicity, the median
time to event was 7.9 months (interquartile range: 5.5 to
11.4 months).
Summaries of baseline levels of and interval changes in
biomarkers are provided in Table 2. Levels of TnI, CRP,
GDF-15, MPO, PlGF, and sFlt-1 increased signiﬁcantly
from baseline to visit 2 (all p < 0.05).
Association between individual biomarkers and incident
cardiotoxicity. We then examined the association between
baseline levels of biomarkers and risk of subsequent
cardiotoxicity (Table 3). The risk of cardiotoxicity was notTable 2 Baseline and Interval Changes in Biomar
Biomarker
Mean Baseline
Levels
Median B
Leve
TnI (ng/l) 6.2  13.7 1.3 (0.7 to
NT-proBNP (pg/ml) 104.0  114.2 71.0 (37.0
CRP (mg/l) 3.5  5.0 1.7 (0.63
GDF-15 (ng/l) 575.4  291.5 500.4 (348.9
MPO (pmol/l) 156.3  159.1 107.1 (76.7
PlGF (pg/ml) 20.8  5.4 19.6 (17.5
sFlt-1 (pg/ml) 343.4  364.6 236.4 (215.4
gal-3 (ng/ml) 18.1  18.3 13.8 (10.8
Values are mean  SD or median (interquartile range). *Median difference
according to Wilcoxon rank sum test.
CRP ¼ C-reactive protein; gal ¼ galectin; GDF ¼ growth differentiation
natriuretic peptide; PlGF ¼ placental growth factor; sFlt ¼ soluble fms-like tyrosigniﬁcantly associated with baseline levels of any biomarker,
although MPO was of marginal signiﬁcance (p ¼ 0.052).
When examining biomarker concentrations at visit 2
(Table 3), only TnI was statistically associated with risk of
cardiotoxicity (HR: 1.36; 95% conﬁdence interval [CI]: 1.07
to 1.73; p ¼ 0.012; per each increase in SD), as has been
previously established (12).
In comparison, interval changes in several biomarkers from
baseline to visit 2 (3 months) were associated with subse-
quent cardiotoxicity (Table 3). For each increase in SD in
TnI (a change of 106.8 ng/l), there was a nearly 40%
increased risk of subsequent cardiotoxicity (HR: 1.38; 95%
CI: 1.05 to 1.81; p ¼ 0.020). MPO had a similar effect size
(HR: 1.34; 95% CI: 1.00 to 1.80; p ¼ 0.048; per each
increase in SD [a change of 355.6 pmol/l]). The distribution
of interval changes in these biomarkers and the incidence of
cardiotoxicity are shown as Kaplan-Meier plots (Online
Figs. 2 and 3). On the basis of these models, the predicted
probabilities of cardiotoxicity as a function of time for
the 10th, 50th, and 90th percentiles of change in TnI and
MPO are displayed in Figures 2A and 2B. At each time
point, those patients at the 90th percentile of change in TnI
or MPO had the greatest predicted risk of cardiotoxicity,
with little difference in the predicted risk between the 10th
and 50th percentile groups. For patients at the 10th
(0.9 ng/l) or 50th (13.9 ng/l) percentiles of DTnI or the
10th (64.8 pmol/l) or 50th (26.3 pmol/l) percentiles of
DMPO, the probability of cardiotoxicity by 15 months
was 23.6% to 26.5%, respectively. For patients at the 90th
(121.8 ng/l or 422.6 pmol/l) percentile for DTnI or DMPO,
the probability of cardiotoxicity by 15 months was 34.2%
to 36.1%.
We noted that increases in GDF-15 and gal-3 levels were
associated with similar effect sizes as TnI and MPO, with
a HR of 1.33 for each biomarker, although neither was
statistically signiﬁcant (p ¼ 0.118 and p ¼ 0.195 per each
increase in SD). There was no evidence of an association
between an early interval change (baseline to visit 2) in
NT-proBNP, CRP, PlGF, or sFlt-1 levels and subsequent
cardiotoxicity.ker Levels Between Baseline and Visit 2
aseline
ls Difference* p Valuey
4.0) 13.9 (2.6 to 31.6) <0.001
to 133.3) 3.0 (38.0 to 26.8) 0.61
to 3.92) 0.6 (0.2 to 4.3) <0.001
to 732.7) 222.0 (27.7 to 467.5) <0.001
to 173.4) 26.3 (27.3 to 114) 0.008
to 23.3) 5.3 (2.9 to 9.3) <0.001
to 272.2) 33.3 (14.7 to 87.3) <0.001
to 18.2) 0.5 (1.5 to 2.2) 0.14
represents the difference between visit 2 and baseline levels. yp value
factor; MPO ¼ myeloperoxidase; NT-proBNP ¼ N-terminal pro–B-type
sine kinase receptor; TnI ¼ troponin I; other abbreviations as in Table 1.
Table 3 Risk of Cardiotoxicity According to Biomarker Levels at Baseline, Visit 2, and Early Interval Changes (Baseline to Visit 2)
Biomarker
Baseline Visit 2 Interval Change
HR (95% CI)* p Valuey HR (95% CI)* p Valuey HR (95% CI)* p Valuey
TnI 1.21 (0.92–1.61) 0.177 1.36 (1.07–1.73) 0.012 1.38 (1.05–1.81) 0.020
NT-proBNP 0.78 (0.48–1.25) NS 0.89 (0.59–1.35) NS 1.11 (0.80–1.54) NS
CRP 1.18 (0.85–1.63) NS 1.07 (0.72–1.60) NS 0.95 (0.52–1.73) NS
GDF-15 0.90 (0.59–1.37) NS 1.26 (0.89–1.78) 0.189 1.33 (0.93–1.92) 0.118
MPO 0.66 (0.44–1.00) 0.052 1.23 (0.93–1.62) 0.149 1.34 (1.00–1.80) 0.048
PlGF 0.88 (0.55–1.40) NS 1.17 (0.82–1.65) NS 1.16 (0.77–1.73) NS
sFlt-1 1.05 (0.70–1.56) NS 0.76 (0.54–1.06) 0.109 0.75 (0.51–1.10) 0.139
Gal-3 0.70 (0.44–1.11) 0.128 0.94 (0.62–1.41) NS 1.33 (0.86–2.05) 0.195
*HR expressed per SD increase in biomarker level. yp > 0.20 are shown as NS.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; NS ¼ not signiﬁcant; other abbreviations as in Table 2.
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813Association between multiple biomarkers and incident
cardiotoxicity. Elevations in absolute levels of TnI at visit
2 in this cohort were previously reported to be associated
with an elevated risk of cardiotoxicity (12). We thus
considered whether the addition of other biomarkers could
provide incremental information to what could be ascribed
to either the TnI level at visit 2 or changes in TnI levels
alone. For these analyses, we selected biomarkers with some
evidence of association with cardiotoxicity in the individual
change models (MPO, GDF-15, gal-3; all with p < 0.20 in
the individual models).
Jointly, interval changes in MPO and TnI levels provided
additive value in predicting subsequent cardiotoxicity, with
HRs of 1.36 (95% CI: 1.04 to 1.79; p ¼ 0.03) and 1.43
(95% CI: 1.10 to 1.86; p ¼ 0.007), respectively, per each
SD increase in interval change. To illustrate the effects of
2 biomarkers in combination, Figures 3A and 3B show the
estimated probability of cardiotoxicity for patients stratiﬁed
into 3 groups. The “none high” group lacked largeFigure 2 Model-Based Probability of Cardiotoxicity According to Per
(A) Bars represent the probability of cardiotoxicity at the 10th, 50th, and 90th percentiles
13.9, and 121.8 ng/l for TnI and 64.8, 26.3, and 422.6 pmol/l for MPO. (B) Curves r
interval changes (baseline and visit 2) in TnI and MPO. MPO ¼ myeloperoxidase; TnI ¼ televations in either biomarker (i.e., quantiles of 0.10 and
0.50 for each biomarker). The “one high” group had
elevated changes in 1 biomarker (i.e., quantile of 0.90 in
either DTnI or DMPO and quantile of 0.10 or 0.50 for the
other biomarker). The “two high” group had elevated
changes in both biomarkers (quantile of 0.90 for both DTnI
and DMPO). Because the “none high” and “one high”
groups incorporated predictions from our multiple biomarker
model for several different combinations of biomarker levels,
the ﬁgures show the range of predictions as a solid block. As
shown in Figures 3A and 3B, the probability of cardiotoxicity
by 15 months in patients without elevations of either
biomarker ranged from 20.4% to 23.4%. The probability of
cardiotoxicity in patients with 1 biomarker with an elevated
change ranged from 31.6% to 33.9% and for patients with
elevated changes in both biomarkers was 46.5%. At all time
points, patients with elevated changes in both biomarkers had
the greatest risk of cardiotoxicity. These ﬁndings suggest that
the combination of multiple markers, such as MPO and TnI,centile Changes in TnI and MPO Between Baseline and Visit 2
of interval changes (baseline and visit 2) in TnI and MPO. These quantiles were 0.9,
epresent the probability of cardiotoxicity at the 10th, 50th, and 90th percentiles of
roponin I.
Figure 3 Model-Based Probability of Cardiotoxicity According to Changes in MPO and TnI Levels
(A) Bars represent the probability of cardiotoxicity according to changes in biomarkers in both TnI and MPO at standardized time intervals. “Both Low” refers to no elevations
in either biomarker (quantiles of 0.1, 0.5), “One High” notes elevations in 1 biomarker (quantile of 0.9 in either TnI or MPO and quantile of 0.1 or 0.5 for the other biomarker),
and “Both High” notes elevations in both biomarkers (quantiles of 0.9). (B) Curves represent the probability of cardiotoxicity according to changes in biomarkers, where “None,”
One High,” and “Two High” represent the same categories as in A. The results are displayed as shaded areas on the graph representing the upper and lower values of the
probability region for each of the 3 categories. Abbreviations as in Figure 2.
Ky et al. JACC Vol. 63, No. 8, 2014
Biomarkers in Cancer Therapy Cardiotoxicity March 4, 2014:809–16
814may improve the detection of doxorubicin and trastuzumab–
induced cardiotoxicity.
The addition of other candidate biomarkers such as
GDF-15 (HR: 1.19; 95% CI: 0.83 to 1.70; p ¼ 0.35) or
gal-3 (HR: 1.31; 95% CI: 0.82 to 2.1; p ¼ 0.26) to a model
containing DTnI did not yield signiﬁcant ﬁndings. Because
the TnI concentration at visit 2 was previously shown to be
associated with cardiotoxicity, in sensitivity analyses, we also
considered joint models containing early changes in MPO,
GDF, or gal-3 levels with the TnI value at visit 2. Again,
only the model containing DMPO (HR: 1.38; 95% CI: 1.05
to 1.81; p ¼ 0.023) retained signiﬁcance for the added
biomarker; here, the HR for troponin was 1.42 (95% CI:
1.10 to 1.81; p ¼ 0.006). The HRs for DMPO in the model
with DTnI or with the absolute level of TnI at visit 2 were
remarkably similar.
In our sensitivity analyses, using the criteria for
cardiotoxicity as deﬁned by a decline in LVEF of at least
10% to <50%, as in the HERA trial (2), there were 11
observed events. No biomarkers were independently asso-
ciated with subsequent cardiotoxicity at a level of p < 0.05
using this criterion. However, using the criterion for car-
diotoxicity as deﬁned by a decline in LVEF of more than
10%, as in the BCIRG006 trial (3), 36 participants met this
deﬁnition. Here, our associations between interval changes
in MPO levels and subsequent cardiotoxicity remained
signiﬁcant (HR: 1.32; 95% CI: 1.1 to 1.6; p ¼ 0.011).
In additional sensitivity analyses, we considered a log2
transformation of a rescaled predictor (to accommodate
negative values), which yielded similar results, albeit gener-
ally with somewhat larger p values.Discussion
Cardiotoxicity associated with cancer therapy is a growing
problem, magniﬁed by the lack of ability to identify patients
at increased risk for cardiotoxicity, both before and early in
therapy. In this study, we ascertained that early changes in
TnI and MPO levels are associated with subsequent car-
diotoxicity; the combination of multiple markers, including
TnI and MPO, may have joint utility in predicting
subsequent cardiotoxicity; and baseline levels appear to have
less prognostic signiﬁcance. Overall, our results suggest that
early interval changes in individual biomarkers may be of
utility in predicting adverse cardiovascular outcomes with
doxorubicin and trastuzumab.
Biomarkers in cardio-oncology have been shown to be of
use in identifying patients with subclinical cardiotoxicity,
particularly related to anthracycline use. One high-impact
study in 703 patients with various malignancies undergoing
high-dose anthracycline chemotherapy showed that multiple
measures of plasma TnI obtained at various time points were
predictive of subsequent cardiotoxicity (15), with a positive
and negative predictive value of 84% and 99%, respectively.
This same group of investigators studied the utility of TnI
in patients with breast cancer treated with trastuzumab (16);
78% of these subjects were previously exposed to anthracy-
cline chemotherapy. Elevated TnI levels were independently
associated with cardiotoxicity, with a HR of approximately
17. However, other investigators have noted that a large
proportion of patients (67%) undergoing sequential therapy
with doxorubicin, trastuzumab, and lapatinib have elevated
TnI levels over the course of chemotherapy (17) and
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815determined that there was no signiﬁcant association between
maximal TnI level and change in LVEF.
Our ﬁndings suggest that there is an association between
TnI positivity and subsequent dysfunction and provide
evidence to support the importance of assessing changes in
biomarkers over time. The utility of TnI appears to lie in
evaluating levels after initial anthracycline chemotherapy
exposure as opposed to baseline. Furthermore, changes in
TnI levels with anthracycline exposure are associated with
subsequent cardiotoxicity.
To our knowledge, we describe for the ﬁrst time an
association between early changes in MPO levels and
subsequent cardiotoxicity induced by treatment with doxo-
rubicin and trastuzumab. MPO is an enzyme secreted by
polymorphonuclear leukocytes that is proatherogenic and
pro-oxidant, causing lipid peroxidation, scavenging of nitric
oxide, and inhibition of nitric oxide synthase (18,19).
In patients with acute coronary syndromes, elevated levels of
MPO are predictive of adverse outcomes, providing additive
value to troponinT (18). Studies in HF also suggest that
MPO is related to an increased risk of more severe disease
(20). Because oxidative stress is hypothesized to be central
to the mechanisms of doxorubicin cardiotoxicity (21), it is
biologically plausible that elevated MPO levels after expo-
sure to doxorubicin are associated with subsequent cardiac
dysfunction (22). Our ﬁndings also suggest that MPO can
be used in combination with TnI to identify a subgroup of
patients that are at a substantially increased risk for
cardiotoxicity. MPO and TnI appear to offer additive
information, with no signiﬁcant correlation (R ¼ 0.13,
p ¼ 0.27), suggesting that these biomarkers are reﬂective of
orthogonal biologic axes. With future study, these markers
in combination may be helpful to further gauge cardiovas-
cular risk.
In terms of other biomarkers, there were no signiﬁcant
associations between cardiotoxicity and elevated levels of
gal-3 and GDF-15. Gal-3 is a 26-kDa protein that is
expressed by macrophages and is believed to be a mediator of
proﬁbrotic pathways, stimulating cardiac ﬁbroblasts to
proliferate and deposit collagen. Gal-3 concentrations are
elevated in patients with acute HF and are predictive of an
increased risk of adverse outcomes (23). GDF-15 is
a member of the transforming growth factor b cytokine
superfamily that is produced in response to oxidative stress,
inﬂammation, and injury (24) and is an emerging marker in
acute coronary syndromes and HF, although its concentra-
tions may be elevated in patients with malignancies. We
found no signiﬁcant association between either GDF-15 or
gal-3 and cardiotoxicity, but further study in larger sample
sizes is justiﬁable.
The lack of an association between CRP levels and
cardiotoxicity is in agreement with the ﬁndings of others
(19). Although early changes in NT-proBNP levels were
not associated with cardiotoxicity, our results do not
exclude the possibility that late changes are predictive of
subsequent adverse cardiovascular events. Neither angiogenicfactor sFlt-1 nor PlGF was associated with subsequent
cardiotoxicity.
Study limitations. Although our study is one of the larger
biomarker studies in patients treated with doxorubicin
followed by trastuzumab, the sample size and the number of
cardiotoxicity events means that we had power to detect only
large associations (HR of approximately 1.8 per SD change
on a linear scale). In fact, the HRs that were detected with
statistical signiﬁcance were of lower magnitude, on the order
of 1.3 to 1.4. Furthermore, the SD in the interval change in
TnI represented a >300% change, suggesting that this
change could not be explained by biological variability alone
(25). We also acknowledge that larger sample sizes may be
needed to optimally deﬁne the metric describing the asso-
ciation between biomarker changes and cardiotoxicity (e.g.,
nonlinear associations). While TnI and MPO were the most
promising candidates in the current study, additional
biomarkers likely deserve further study in larger sample sizes.
Given our small sample size, we were precluded from
adequately assessing the impact of all potential confounders.
It is also critical that our ﬁndings are further validated before
application to clinical practice. Finally, it is not possible to
differentiate whether our ﬁndings are secondary to anthra-
cyclines, trastuzumab, or a combination of the 2 agents.
To answer this question, future biomarker studies in patients
treated with each agent individually are necessary. None-
theless, these ﬁndings are very relevant to a population of
patients with breast cancer undergoing combination therapy.Conclusions
Our study conﬁrms that TnI is associated with subsequent
cardiac dysfunction and HF in patients with breast cancer
undergoing sequential therapy with doxorubicin and tras-
tuzumab. We found that MPO is a potential marker of
incident cardiac dysfunction in this population. Finally, our
results suggest that a multimarker approach may increase the
sensitivity of cardiotoxicity risk prediction in patients treated
with anthracyclines, taxanes, and trastuzumab.Acknowledgments
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